Michael Rowbotham
Directeur/Membre du Conseil chez The University of California, San Francisco
Postes actifs de Michael Rowbotham
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| The University of California, San Francisco | Directeur/Membre du Conseil | - | - |
Historique de carrière de Michael Rowbotham
Anciens postes connus de Michael Rowbotham
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2006 | - |
Formation de Michael Rowbotham
| The University of California, San Francisco | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Bourse
- Insiders
- Michael Rowbotham
- Expérience
